Abstract
Cancer can invade and destroy any part of the body, representing a grand social, public health, and economic challenge. Chemotherapy plays a crucial role in cancer treatment, and in recent decades, hundreds of anticancer chemotherapeutics have been introduced. Nevertheless, multidrug resistance and side effects are the main obstacles to successful cancer therapy, highlighting the pressing requirement for the development of new chemotherapeutics to address the above issues. Indole hybrids not only have the potential to surmount drug resistance and adverse effects caused by individual components but also can enhance efficacy and improve pharmacokinetic characteristics since hybrid molecules can concurrently regulate multiple targets within cancer cells. Moreover, numerous indole hybrids exemplified by mobocertinib (indole-pyrimidine hybrid) and osimertinib (indole-quinazoline hybrid) have already been utilized in clinical cancer treatment. Therefore, indole hybrids have emerged as valuable scaffolds for the treatment and eradication of cancer. This review aims to elucidate the current landscape of indole-(fused) pyri(mi)dine hybrids, including indole-quinolines/quinolinones, indole-pyridines, indole-pyrimidines, and indole-fused pyrimidines, with in vivo antitumor therapeutic potential, offering effective candidates for in-depth preclinical evaluations, encompassing articles published from 2021 onward.